This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Council of Scientific and Industrial Research. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Sriramoju Bharat Kumar: Innovator in Antimalarial Compounds
Introduction
Sriramoju Bharat Kumar is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antimalarial compounds. His work focuses on synthesizing novel compounds that exhibit remarkable biological activity.
Latest Patents
Sriramoju Bharat Kumar holds a patent for "Antimalarial Baylis-Hillman adducts and a process for the preparation thereof." This invention is directed towards the synthesis of new chloropyridine skeleton-based compounds, specifically Baylis-Hillman adducts, which demonstrate significant in vitro anti-malarial activity. These compounds have shown effectiveness against both chloroquine-sensitive and chloroquine-resistant strains of malaria. The anti-malarial compounds inhibit mature schizonts in vitro, showcasing their potential as therapeutic agents.
Career Highlights
Sriramoju Bharat Kumar is affiliated with the Council of Scientific and Industrial Research, where he conducts research and development in the field of medicinal chemistry. His innovative work has contributed to advancements in the fight against malaria, a disease that continues to pose a significant health challenge globally.
Collaborations
Some of his notable coworkers include Puli Narender and Banda Gangadasu, who have collaborated with him on various research projects. Their combined efforts have furthered the understanding and development of effective antimalarial treatments.
Conclusion
Sriramoju Bharat Kumar's contributions to the field of antimalarial research highlight the importance of innovation in addressing global health issues. His patented compounds represent a promising avenue for future therapeutic developments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
